Knowledge HQ

This study presents the design of a phase I clinical trial for NEXTGEN-TIL, a product selected for neoantigen recognition in solid tumors. It details preclinical expansion from biopsies. G-Rex® vessels were used for clinical-scale GMP validation of the rapid expansion protocol (REP) to obtain sufficient cell doses.

This study compares Solupore and electroporation for manufacturing multi-edited CAR-T cells. Solupore-transfected cells showed higher viability, TSCM retention, and in vivo efficacy. 24-well G-Rex® were used to assess cell proliferation and cytokine production, supporting metabolic health analysis.

This poster evaluates cGMP T cell expansion protocols using ImmunoCult reagents across G-Rex® (6M plate and 50M bottle), Xuri, and PBS-MINI bioreactors. G-Rex® produced high cell densities and yields of functional T cells, including central memory subsets, suitable for clinical manufacturing.

This study describes the MC3 protocol for lung TIL manufacturing, which simplifies the process by using G-Rex® for both preREP and REP phases and replacing feeder cells with CD3/CD28 nanobeads. The method reduced culture time and costs while producing TILs with superior cytotoxicity against tumor organoids.

The authors developed 'enGager', a Cas9 fusion system that tethers cssDNA donors to enhance non-viral targeted integration. Used to engineer CD19/CD22 dual CAR-T cells. Post-electroporation, T cells were transferred to G-Rex® 24-well plates for expansion, achieving high knock-in efficiency and cell viability.

This abstract presents SENTI-202, a logic-gated CAR-NK therapy for AML. The EMCN inhibitory CAR protects healthy HSCs from off-tumor toxicity. R&D scale CAR-NK cell manufacturing utilized 1L G-Rex® for expansion, achieving high cell numbers and viability while maintaining logic gate function.

This study demonstrates that tuning the affinity of the TAC receptor's TCR-binding domain improves in vivo anti-tumor potency. CLDN18.2-TAC T cells were engineered and expanded using the G-Rex® system. Lower affinity UCHT1 variants led to superior functional outcomes in solid tumor models.

This review analyzes automated cell therapy manufacturing systems. It highlights the G-Rex® as a key technology for simplified static expansion compared to flasks. It notes that the Multiply Labs robotic cluster integrates G-Rex® 100M for automated, parallel T cell expansion.

This study establishes an optimized platform for expanding and genetically modifying NK cells. Using KBM581 medium with serum replacement in 24-well G-Rex® plates, the authors achieved over 5000-fold expansion in 14 days. The protocol supports efficient viral transduction and gene editing of NK cells.

This study introduces RESET, a two-component receptor system engaging the endogenous TCR with drug-regulated control. RESET-T cells exhibited superior sensitivity and potency compared to CARs. G-Rex® vessels were used for the culture and expansion of the engineered T cells during the study.

This protocol describes the isolation and feeder-cell-based expansion of NK cells. To demonstrate clinical scalability, the method was tested on GMP-grade G-Rex® 100M platforms, achieving clinically relevant numbers of highly pure and functional NK cells suitable for adoptive therapy.

This paper details the GMP manufacturing of CISH KO TILs for GI cancers. Tumor fragments were outgrown in 24-well G-Rex® plates, and selected TILs were expanded in 100 cm² G-Rex® vessels. An automated liquid handling system was developed to perform media exchanges directly in the G-Rex® 24 plates.